JP2008511631A - ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール - Google Patents

ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール Download PDF

Info

Publication number
JP2008511631A
JP2008511631A JP2007530093A JP2007530093A JP2008511631A JP 2008511631 A JP2008511631 A JP 2008511631A JP 2007530093 A JP2007530093 A JP 2007530093A JP 2007530093 A JP2007530093 A JP 2007530093A JP 2008511631 A JP2008511631 A JP 2008511631A
Authority
JP
Japan
Prior art keywords
bicyclo
pyrimidin
imidazol
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007530093A
Other languages
English (en)
Japanese (ja)
Inventor
ウェン−チャーン リー，
リホン サン，
クラウディオ チュアキ，
ジャスウィンダー シン，
フェン シャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431931&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008511631(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2008511631A publication Critical patent/JP2008511631A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
JP2007530093A 2004-08-31 2005-08-24 ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール Withdrawn JP2008511631A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60604504P 2004-08-31 2004-08-31
PCT/US2005/030133 WO2006026306A1 (fr) 2004-08-31 2005-08-24 Pyrimidinylimidazoles utilises comme inhibiteurs de tgf-beta

Publications (1)

Publication Number Publication Date
JP2008511631A true JP2008511631A (ja) 2008-04-17

Family

ID=35431931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007530093A Withdrawn JP2008511631A (ja) 2004-08-31 2005-08-24 ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール

Country Status (6)

Country Link
EP (1) EP1786802A1 (fr)
JP (1) JP2008511631A (fr)
AU (1) AU2005280168A1 (fr)
CA (1) CA2578630A1 (fr)
TW (1) TW200621753A (fr)
WO (1) WO2006026306A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090997A1 (fr) 2010-12-27 2012-07-05 京都府公立大学法人 CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
JP2017513922A (ja) * 2014-03-11 2017-06-01 ワン、イウェンＷＡＮＧ， Ｙｉ−Ｗｅｎ 瘢痕形成を軽減する医薬組成物及び方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044509A2 (fr) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Procede pour traiter des lesions vasculaires
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
CN101743234A (zh) 2007-04-30 2010-06-16 雅培制药有限公司 二酰甘油o-酰基转移酶1型酶的抑制剂
CN101910153B (zh) * 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2012167261A2 (fr) * 2011-06-03 2012-12-06 Yale University Compositions et méthodes de traitement et de prévention d'une sténose néointimale
WO2013014262A1 (fr) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de diagnostic et de traitement du syndrome de myhre
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
EP3947737A2 (fr) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
CA2498047C (fr) * 2002-09-18 2009-05-19 Pfizer Products Inc. Composes d'imidazole utilises en tant qu'inhibiteurs du facteur de croissance transformant (tgf)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090997A1 (fr) 2010-12-27 2012-07-05 京都府公立大学法人 CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
JP2017513922A (ja) * 2014-03-11 2017-06-01 ワン、イウェンＷＡＮＧ， Ｙｉ−Ｗｅｎ 瘢痕形成を軽減する医薬組成物及び方法

Also Published As

Publication number Publication date
AU2005280168A1 (en) 2006-03-09
TW200621753A (en) 2006-07-01
EP1786802A1 (fr) 2007-05-23
WO2006026306A1 (fr) 2006-03-09
CA2578630A1 (fr) 2006-03-09

Similar Documents

Publication Publication Date Title
JP2008511631A (ja) ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール
US7612094B2 (en) Tri-substituted heteroaryls and methods of making and using the same
US20080171755A1 (en) Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
US7691865B2 (en) Pyrazolopyridines and methods of making and using the same
US20060264440A1 (en) Pyrazoles and methods of making and using the same
JP6094975B2 (ja) Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類
US20100035918A1 (en) Imidazolone Compounds and Methods of Making and Using the Same
JP2006502164A (ja) イミダゾロピリジンならびにその生成および使用方法
JP2006502164A5 (fr)
WO2009009059A1 (fr) Composés spiro en tant qu'antagonistes du tgf-bêta
US20100105714A1 (en) Furanone Compounds and Methods of Making and Using The Same

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20081104